Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress

SEATTLE, Jan. 6, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) management will host a conference call on Friday, January 7, 2011 at 9:00 a.m. ET to provide updates on U.S. commercialization progress, European strategy for PROVENGE, and pipeline progress.

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-642-1687 or +1-706-645-9291 for international callers; the conference ID number is 35063654. The replay will be available from 12:00 p.m. ET on Friday, January 7 until 11:59 p.m. ET on Monday, January 10.  In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

SOURCE Dendreon Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED